title: Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
abstract: BACKGROUND
  We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival.
  
  
  METHODS
  Sixty-three patients suffering from unresectable and non-embolizable HCC and who had objectively measurable tumors, adequate liver and renal function, and adequate bone-marrow reserve were enrolled in this study. The therapeutic regimen consisted of cisplatin 80 mg/m(2) and mitoxantrone 6 mg/m(2) intravenously on day 1, and 5-FU 450 mg/m(2) per day continuous infusion for a period of 5 days. Univariate and multivariate analyses of patient and disease characteristics were used to identify factors predicting patient response and survival.
  
  
  RESULTS
  The objective response was 23.8% (95% confidence interval [CI], 13.0-34.6%). The median survival for all 63 patients was 4.9 months (95% CI, 3.2-6.6 months). The median time to progression was 2.5 months (95% CI, 1.7-3.3 months). Multivariate analysis identified only performance status ( P = 0.050) and liver tumor size ( P = 0.012) as being significantly related to patient objective response. Independent variables associated with a better patient survival included: the absence of ascites ( P = 0.003), a lower total bilirubin level ( P = 0.026), and the patient being a positive chemotherapy responder ( P = 0.009).
  
  
  CONCLUSIONS
  The response rate to an FMP regimen was still unsatisfactory, although a specific subgroup of patients (good performance status, smaller liver tumor mass, good liver reserve, and distant metastasis) may benefit from this regimen.We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei 105, Taiwan.
authors.forename: Tsai-Shen
authors.initials: TS
authors.lastname: Yang
authors.forename: Hsien-Khun
authors.initials: HK
authors.lastname: Chang
authors.forename: Jen-Shi
authors.initials: JS
authors.lastname: Chen
authors.forename: Yung-Chang
authors.initials: YC
authors.lastname: Lin
authors.forename: Chi-Ting
authors.initials: CT
authors.lastname: Liau
authors.forename: Wen-Cheng
authors.initials: WC
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D008942:Mitoxantrone; D002945:Cisplatin; D005472:Fluorouracil